Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109874 | 0.98 | MGLL (0.33) | MGLLP2RX7GSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL15385166 | 0.76 | POLB (0.46) | MGLLGSK3BDYRK1A | |
| SCHEMBL24656037 | 0.73 | GSK3B (0.32) | MGLLGSK3BDYRK1A | |
| SCHEMBL929279 | 0.73 | POLB (0.47) | MGLLGSK3BDYRK1A | |
| SCHEMBL17611615 | 0.73 | MGLL (0.33) | MGLLGSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL1509240 | 0.72 | DPP4 (0.31) | MGLLP2RX7 | |
| Hydrochloric Acid SCHEMBL332198 | 0.72 | MGLL (0.35) | MGLL | |
| Hydrochloric Acid SCHEMBL30980060 | 0.70 | MAPT (0.35) | GSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL108798 | 0.69 | MGLL (0.41) | MGLLGSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL573084 | 0.69 | MGLL (0.34) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025044946-A1 | COMPOUND ACTING AS MRGPRX2 ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2025-03-06 | — | — | WO | disclosed |
| CN-119504738-A | Compounds as MRGPRX2 antagonists, methods of preparation and use thereof | 武汉人福创新药物研发中心有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-112041319-B | Triazole, imidazole and pyrrole fused piperazine derivatives and their use as mGlu5Use of modulators of receptors | 利康化学与制药工业有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-3740478-B1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | disclosed |
| US-11591337-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of mGlu5 receptors | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) | 2023-02-28 | — | — | US | disclosed |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | UCB Biopharma SRL (BE) | 2022-10-18 | — | — | US | disclosed |
| US-20210053952-A1 | Fused Imidazole Derivatives as IL-17 Modulators | UCB Biopharma SRL (BE) | 2021-02-25 | — | — | US | disclosed |
| US-20210047331-A1 | TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS | RECORDATI IND CHIMICA E FARMACEUTICA S P A (IT) | 2021-02-18 | — | — | US | disclosed |
| EP-3743429-A1 | TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 2020-12-02 | — | — | EP | disclosed |
| EP-3740478-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-11-25 | — | — | EP | disclosed |
| WO-2019145214-A1 | TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A (IT) | 2019-08-01 | — | — | WO | disclosed |
| EP-2424869-B1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LTD (GB) | 2016-06-22 | — | — | EP | disclosed |
| US-8501946-B2 | 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | IL17A, IL2, IL23R | MGLL 4677/4885P2RX7 1500/4885GSK3B 2786/4885 |
| US-20210047331-A1 | TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS | GRM5, GRIK5, GRIN3A | MGLL 2208/4885P2RX7 402/4885GSK3B 3084/4885 |
| US-20210053952-A1 | Fused Imidazole Derivatives as IL-17 Modulators | IL17A, IL2, IL23R | MGLL 4677/4885P2RX7 1500/4885GSK3B 2786/4885 |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | P2RX7, P2RX6, P2RX3 | MGLL 4399/4885P2RX7 1/4885GSK3B 1963/4885 |
| US-11591337-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of mGlu5 receptors | GRM5, GRIK5, GRM1 | MGLL 2368/4885P2RX7 312/4885GSK3B 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.